Epigenomics AG is a molecular diagnostics company, which engages in the development and commercializing of proprietary products for the screening and diagnosis of cancer. The company is headquartered in Heidelberg, Baden-Wuerttemberg and currently employs 3 full-time employees. The company went IPO on 2004-07-19. The company develops and commercializes blood-based diagnostic products across multiple cancer indications. The firm's main product is Epi proColon, a blood test for colorectal cancer screening. Along with the blood-based tests the Company offers services related to research, product development, regulatory approval and manufacturing of in-vitro diagnostic (IVD) products. The company also offers Epi proLung, a blood-based test that detects the presence of lung cancer in blood plasma. The firm is present in Europe and the United States.
Follow-Up Questions
EPGNF 股票的价格表现如何？
EPGNF 的当前价格为 $0，在上个交易日 decreased 了 0%。
Epigenomics AG 的主要业务主题或行业是什么？
Epigenomics AG 属于 Biotechnology 行业，该板块是 Health Care
